- Codiak BioSciences Inc (NASDAQ:CDAK) voluntarily filed for protection under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware and will seek to pursue a sale process for its assets.
- The company began a marketing process ahead of the Chapter 11 filing to determine the level of market interest and is in ongoing discussions with several parties.
- The company expects to consummate a sale of the entire business or its core assets.
- Codiak BioSciences’ executive management team, including the CEO, CFO, Chief Medical Officer, and Chief Scientific Officer, will depart effective April 7.
- Douglas Williams (CEO) will remain on the Board.
- Konstantin Konstantinov, (Chief Technology Officer) will remain with the company.
- In August, the company announced a reprioritization of its clinical and research initiatives, accelerating discussions related to potential strategic corporate and program-based partnerships and restructuring operations to support a streamlined set of priorities.
- Codiak BioSciences also raised $20 million via equity in September last year.
- Price Action: CDAK shares are down 54.40% at $0.20 on the last check Monday.
Antelope Enterprise Holdings Announces Pricing Of ~$1.0M Registered Direct Offering; The Company Will Issue 1,666,667 Registered Common Shares At A Purchase Price Of $0.60 Per Share
JINJIANG, China, Sept. 30, 2022 /PRNewswire/ -- Antelope Enterprise Holdings, Ltd. (f/k/a China Ceramics Co., Ltd.) (NASDAQ Capital Market: AEHL) (the "Company"), a Chinese manufacturer of
